Aardvark Therapeutics is set to disclose results from its phase 3 Prader-Willi syndrome (PWS) development program following the FDA’s complete clinical hold on the studies.
Aardvark, a San Diego-based company, voluntarily halted a phase 3 study of ARD-101 in March to investigate its use as a treatment for hyperphagia or excessive eating in PWS. A cardiac safety signal in a healthy volunteer study triggered the pause. The biotech later that month extended the halt to trials of a phase 2 compound, ARD-201, which is a combination of ARD-101 and a DPP-4 inhibitor.
Up to now, Aardvark’s efforts have been entirely voluntary as the biotech stated that it initially halted the research into the gut-targeting taste receptor agonist, ARD-101, “out of an abundance of caution.” But now the FDA has issued a complete clinical hold for all studies involving ARD-101, including the phase 3 PWS trial and its open-label extension.
In March, Aardvark had planned to present topline results in the third quarter, but that was before it called it a day on the studies. Aardvark’s cash runway is expected to cover operations into the second quarter of 2027, giving it a short period of time to make its numbers and use the results to raise money or attract a partner to secure its future.
Aardvark’s cash runway has been extended until mid-2027. The program has already been on hold for 11 weeks and is now fully in clinical hold, which is narrowing the time that the biotech has to finish the trial, present the results, and decide on the fate of the program.
Aardvark will present data from the phase 3 trial and open-label extension, given the pressure. When the biotech halted the studies, it had dosed a total of 68 patients in the randomized phase 3 trial and 19 in the extension.
The data will be unblinded on the patients, which will enable Aardvark to “assess the overall available efficacy and safety data and inform an informed decision on further development of the ARD-101 program,” the company stated. Aardvark ended its trading at $5.65, down 16%. As of February, the stock was trading at $12.49, before the news of the voluntary pause arrived.
Aardvark had earlier submitted data that suggested that the phase 3 dose isn’t likely to produce the events that led to the pause. Twice the phase 3 dose (without titration) caused more than the 25% cardiac QRS prolongation marker in two of eight healthy volunteers. A later study of the phase 3 dose saw one case of cardiac QRS prolongation of less than 25% in 23 people.
Aardvark is preparing to examine Phase 3 clinical trial data earlier than expected following a recent FDA clinical hold affecting its investigational therapy program. The decision reflects the company’s effort to assess safety findings, evaluate treatment performance, and determine the best path forward for future development.
The latest update has drawn attention from investors and healthcare analysts monitoring regulatory actions within the biotechnology industry.
Aardvark Responds to FDA Hold
The FDA hold prompted Aardvark to accelerate its review of ongoing Phase 3 study data in order to better understand the impact of the regulatory concerns. Company officials stated that the earlier analysis may help identify trends related to safety, efficacy, and patient outcomes.
Clinical holds are typically issued when regulators require additional information or further evaluation before allowing trials to continue without restrictions.
The FDA development involving Aardvark has generated mixed reactions among investors and market analysts. Some observers remain cautious due to regulatory uncertainty, while others believe the company’s decision to review data early demonstrates a proactive approach to addressing potential issues.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
